1. Screening of Atherosclerotic Druggable Targets from the Proteome Network of Differentially Expressed Genes
- Author
-
Allan Blessing Harison Raj, Subramaniyan Manibalan, and Anant Achary
- Subjects
0303 health sciences ,Proteome ,Gene Expression Profiling ,Druggability ,Computational Biology ,Computational biology ,Biology ,030226 pharmacology & pharmacy ,Gene Expression Regulation, Neoplastic ,03 medical and health sciences ,Gene Ontology ,0302 clinical medicine ,Differentially expressed genes ,Drug Discovery ,Molecular Medicine ,Gene Regulatory Networks ,Protein Interaction Maps ,Gene ,030304 developmental biology - Abstract
Differently expressed genes of atherosclerotic sample analysis are helpful to sort the prominent genes that influence the plaque formation and progression. Scientific evidence-based protein-protein interaction network (PPIN) studies were used to find hub proteins in complex disease conditions. Druggable capacity is one of the important parameters to confirm as a successful drug target. Construction of protein interaction network and principal node analysis (PNA) on atherosclerotic data sets lead to screen the hub proteins. Furthermore, druggable property of protein pocket confirms the targetability of susceptible target candidates and for target selection. Differentially expressed genes are identified through GEO2R analyzer on data sets of various atherosclerotic samples. STRING database and Cytoscape are employed to construct PPIN. Targets were identified by PNA such as centrality measures and clustering algorithm. Gene Ontology enrichment also used as one of the screening parameters to filter the candidates related to atherosclerotic terms. Topological evaluation of target protein was successfully done by ITASSER and GROMACS, respectively. Grid-based principle of DoGSiteScorer is utilized for druggability analysis. Six proteins such as integrin alpha L (ITGAL), metallothionein 1F (MT1F), metallothionein 1X (MT1X), P-selectin glycoprotein ligand-1 (SELPLG), solute carrier family 30 A, zinc transporter protein (SLC30A1), and TNFSF13B are screened as potential biomarkers through network-based analysis. Among the six, ITGAL, SELPLG, SLC30A1, and TNSF13B are identified as better prioritized atherosclerotic targets through druggability efficiency.
- Published
- 2021